- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03076281
Metformin Hydrochloride and Doxycycline in Treating Patients With Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery
A Phase II Study of Metformin, Doxycycline, or a Combination of Both Agents in Head and Neck Squamous Cell Carcinoma
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. To determine if treatment with metformin hydrochloride (metformin), doxycycline, or a combination of metformin and doxycycline can increase the percentage of stromal cells that express CAV1 in patients with squamous cell carcinoma of the head and neck.
SECONDARY OBJECTIVES:
I. To determine the effect of metformin, doxycycline, or metformin and doxycycline treatment on the percentage of tumor cells that are apoptotic as determined by the TdT-Mediated dUTP Nick End Labeling Assay (TUNEL) assay, and express MCT4, MCT1, BGAL, and TOMM20 in squamous carcinoma of head and neck region tumor cells.
II. To assess safety and tolerability of metformin, doxycycline, or metformin and doxycycline treatment in subjects with squamous cell carcinoma of the head and neck.
TERTIARY OBJECTIVES:
I. To assess the effect of metformin, doxycycline, or metformin and doxycycline therapy on the metabolic profile of cancer cells and stroma using mass spectroscopy imaging (MSI) on paired samples, comparing metabolite profiles in the pre-treatment and post-treatment tumor samples.
II. To assess the effect of metformin, doxycycline, or metformin and doxycycline therapy on the metabolic state of the patient as characterized serologically by: erythrocyte sedimentation rate, exosome evaluation, metabolomics profile, and micro ribonucleic acid (RNA) expression profiles and physiologically by performing a nutritional assessment via a nutritionist-mediated 3-day dietary recall and comparing a patient's estimated dietary intake against their estimated caloric needs.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19107
- Sidney Kimmel Cancer Center at Thomas Jefferson University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosis of head and neck squamous cell carcinoma that is either biopsy proven or suspected based on history, physical, and or radiographic findings, and who are planned for definitive resection of the tumor without the use of neoadjuvant chemotherapy or radiation therapy at TJUH are eligible to participate.
- Subjects must be ≥ 18 years of age at time of consent.
- Patient must be able to swallow pills.
- Patients with serum creatinine levels less than 1.5 mg/dL
- Women of childbearing potential must have a negative urine or blood pregnancy test within 14 days of study enrollment.
- Informed Consent: All subjects must be able to comprehend and sign a written informed consent document.
- ECOG Performance status ≤1
Exclusion Criteria:
Subjects that do not have a baseline tumor specimen/biopsy prior to starting study medications.
a. Tumor specimens do not need to be at Jefferson at time of eligibility determination. Tumor specimens held at outside institutions should be requested for analysis of pre-treatment tumor vs post-treatment tumor.
- Subjects who are pregnant or breastfeeding, or may become pregnant during metformin and doxycycline administration.
- Received prior cancer therapy for the HNSCC that is being resected.
- Subjects on metformin or doxycycline for any reason during the preceding 4 weeks.
- Diabetic subjects that are managed by taking metformin or insulin
- Subjects who have received iodinated contrast dye must wait 12 hours prior to starting Metformin. If a CT scan with contrast is scheduled after screening and consent, the metformin cannot be taken until after the CT with contrast has been completed and they have waited 12 hours.
- Patients with serum creatine ≥1.5 mg/dL
- Patients with history of lactic or any other metabolic acidosis.
- Patients with history of congestive heart failure stage III or greater.
- Patients scheduled for definitive cancer surgical resection less than 7 days from beginning of study drug administration or greater than 6 weeks from beginning study drug administration.
- Patients with history of hepatic dysfunction or hepatic disease and abnormal liver function tests defined as AST, ALT, Alk Phos, and or total bilirubin greater than 2.5 times the upper limit of normal. Patients who have a history of hepatic dysfunction or hepatic disease and normal liver function tests will be eligible to participate.
- Patients with a current history (in the past 30 days) of heavy drinking which is defined in accordance with CDC definition as more than 8 drinks per week for women and more than 15 drinks per week for men. A standard drink contains .6 ounces of pure alcohol. Generally, this amount of pure alcohol is found in 12-ounces of beer, 8-ounces of malt liquor, 5-ounces of wine, 1.5-ounces or a "shot" of 80-proof distilled spirits or liquor (e.g., gin, rum, vodka, or whiskey). While on study, patients should limit their alcohol consumption to no more than 8 drinks per week for women and no more than 15 drinks per week for men.
- Patient with prior allergic reaction to metformin, doxycycline, or any other tetracycline antibiotic in the past.
Patient is on medications that are contraindicated with metformin or doxycycline under current FDA recommendations. The following is a list of medications identified as class D (consider therapy modification) when treatment with metformin or doxycycline is considered:
Class D:
- Bismuth Subsalicylate
- Cimetidine
- Iodinated cont
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Arm A (metformin hydrochloride)
Patients receive metformin hydrochloride PO daily on days 1-3 and twice daily starting on day 4 to the day prior to surgery in the absence of disease progression or unacceptable toxicity
|
Given orally
Other Names:
|
EXPERIMENTAL: Arm B (doxycycline)
Patients receive doxycycline PO every 12 hours on days 1 to the day prior to surgery in the absence of disease progression or unacceptable toxicity.
|
Given orally
Other Names:
|
EXPERIMENTAL: Arm C (metformin hydrochloride, doxycycline)
Patients receive metformin hydrochloride PO daily on days 1-3 and twice daily starting on day 4 to the day prior to surgery and doxycycline PO every 12 hours on days 1to the day prior to surgery in the absence of disease progression or unacceptable toxicity.
|
Given orally
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in percent of CFS expressing CAV-1 at an intensity of 1+ or greater assessed in tumor-associated stroma cells by immunohistochemistry (IHC)
Time Frame: Baseline to 30 days after last drug dose
|
Within-patient change in IHC scores will be analyzed using the Wilcoxon signed-rank test.
Comparisons will be made between pretreatment and post-treatment within each of the cohorts
|
Baseline to 30 days after last drug dose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of adverse events as assessed by National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0
Time Frame: Up to 30 days after last drug dose
|
Safety will be provided in descriptive tables.
|
Up to 30 days after last drug dose
|
Change in percent of tumor cells expressing MCT4, that are TUNEL positive and that express BGAL
Time Frame: Baseline to 30 days after last drug dose
|
Analysis will be performed using the Wilcoxon signed-rank test.
|
Baseline to 30 days after last drug dose
|
Change in percent of tumor cells expressing MCT4, that are TUNEL positive and that express MCT1
Time Frame: Baseline to 30 days after last drug dose
|
Analysis will be performed using the Wilcoxon signed-rank test.
|
Baseline to 30 days after last drug dose
|
Change in percent of tumor cells expressing MCT4, that are TUNEL positive and that express MCT4
Time Frame: Baseline to 30 days after last drug dose
|
Analysis will be performed using the Wilcoxon signed-rank test.
|
Baseline to 30 days after last drug dose
|
Change in percent of tumor cells expressing MCT4, that are TUNEL positive and that express TOMM20
Time Frame: Baseline to 30 days after last drug dose
|
Analysis will be performed using the Wilcoxon signed-rank test.
|
Baseline to 30 days after last drug dose
|
Collaborators and Investigators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Head and Neck Neoplasms
- Neoplasms, Squamous Cell
- Carcinoma, Squamous Cell
- Squamous Cell Carcinoma of Head and Neck
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Anti-Infective Agents
- Anti-Bacterial Agents
- Antiprotozoal Agents
- Antiparasitic Agents
- Antimalarials
- Metformin
- Doxycycline
Other Study ID Numbers
- 16D.703
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Larynx
-
Mayo ClinicEnrolling by invitationLarynx | Larynx Disease | Laryngectomy | Larynx Stenosis | Larynx FractureUnited States
-
University of Texas Southwestern Medical CenterCompletedEarly-stage Glottic Larynx CancerUnited States
-
Latin American Cooperative Oncology GroupMerck Sharp & Dohme LLCActive, not recruitingSquamous Cell Carcinoma of LarynxBrazil
-
University of LeipzigUniversity of Kiel; University of Cologne; University of Jena; Technical University... and other collaboratorsNot yet recruitingLaryngeal Cancer | Squamous Cell Carcinoma of Head and Neck | Laryngeal Neoplasms | Squamous Cell Carcinoma of the Larynx | Hypopharyngeal Squamous Cell Carcinoma | Laryngeal Squamous Cell Carcinoma | Laryngectomy; Status | Squamous Cell Carcinoma of Larynx | Squamous Cell Carcinoma of the Larynx Stage... and other conditions
-
Danish Head and Neck Cancer GroupCompletedHNSCC,Larynx, Pharynx and Oral CavityDenmark
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedHuman Papilloma Virus Infection | Stage III Squamous Cell Carcinoma of the Hypopharynx | Stage III Squamous Cell Carcinoma of the Larynx | Stage III Squamous Cell Carcinoma of the Oropharynx | Stage III Verrucous Carcinoma of the Larynx | Stage IV Squamous Cell Carcinoma of the Hypopharynx | Stage... and other conditionsUnited States
-
Hacettepe UniversityCompletedLarynx Cancer | Larynx CarcinomaTurkey
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyTerminatedTongue Cancer | Stage III Squamous Cell Carcinoma of the Hypopharynx | Stage III Squamous Cell Carcinoma of the Larynx | Stage III Squamous Cell Carcinoma of the Oropharynx | Stage III Verrucous Carcinoma of the Larynx | Stage IV Squamous Cell Carcinoma of the Hypopharynx | Stage IVA Squamous... and other conditionsUnited States
-
Radboud University Medical CenterDutch Cancer SocietyCompleted
-
University Hospitals Cleveland Medical CenterCompleted
Clinical Trials on Metformin Hydrochloride
-
Haisco Pharmaceutical Group Co., Ltd.The Fourth Hospital of Hebei Medical UniversityRecruitingDiabetic Neuropathies | Diabetic Neuropathy PeripheralChina
-
University of UtahNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)Recruiting
-
University of ArizonaNational Cancer Institute (NCI)RecruitingOral Leukoplakia | ErythroplakiaUnited States, Canada
-
National Cancer Institute (NCI)RecruitingLung CarcinomaUnited States, Canada
-
GlaxoSmithKlineCompleted
-
UConn HealthCompletedAging | Vaccine Response Impaired | Age-Related ImmunodeficiencyUnited States
-
Johns Hopkins UniversityBaylor College of Medicine; National Heart, Lung, and Blood Institute (NHLBI); Temple UniversityNot yet recruitingAsthma | Overweight and Obesity | Asthma Chronic
-
RenJi HospitalCompleted
-
Laboratorios Silanes S.A. de C.V.Completed
-
Bing HeActive, not recruitingPolycystic Ovary SyndromeChina